BMJ 2003;326:251-252 ( 1 February )

Papers

Controlled trial of effect of documented cardiovascular risk scores on prescribing

L M L Hall, medical student, R T Jung, consultant, G P Leese, consultant. 

Diabetes Centre, Ninewells Hospital, Dundee DD1 9SY

Correspondence to: G P Leese
graham.leese@tuht.scot.nhs.uk

The first 150 words of the full text of this article appear below.

Cardiovascular disease causes the death of around 80% of patients with type 2 diabetes.¹ However, risk factors for cardiovascular disease in such patients are often untreated² despite the proved benefits of intervention. ^{3 4} One way to help clinicians identify patients at high risk of cardiovascular disease is to use cardiovascular primary prevention risk tables. These tables integrate the multiple risk factors into a single score. We did a pilot study to test the hypothesis that documentation of a cardiovascular risk score in the case notes would improve the management of cardiovascular risk factors.

	Participants, methods, and results

We recruited patients with type 2 diabetes who had no history of cardiovascular disease or renal disease. All patients were aged 35-75 years and attending a hospital outpatient clinic. We recruited 323 patients (167 men and 156 women) attending the clinic consecutively. Patients were seen by one of six doctors who were unaware of the ongoing project. We allocated patients alternately to the experimental . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Evaluating cardiovascular risk assessment for asymptomatic people

Ian A Scott
BMJ 2009 338: a2844. [Extract] [Full Text]

Cardiovascular risk scores and prescribing in diabetes

Jamie Smith, Roger Corrall, Graham P Leese, Lesley Hall, and Roland Jung
BMJ 2003 326: 882. [Extract] [Full Text]

This article has been cited by other articles:

• Cooney, M. T., Dudina, A. L., Graham, I. M. (2009). Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians.. J Am Coll Cardiol 54: 1209-1227 [Abstract] [Full text]  
• Redberg, R. F., Benjamin, E. J., Bittner, V., Braun, L. T., Goff, D. C. Jr, Havas, S., Labarthe, D. R., Limacher, M. C., Lloyd-Jones, D. M., Mora, S., Pearson, T. A., Radford, M. J., Smetana, G. W., Spertus, J. A., Swegler, E. W. (2009). ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research.. J Am Coll Cardiol 54: 1364-1405 [Full text]  
• WRITING COMMITTEE MEMBERS, , Redberg, R. F., Benjamin, E. J., Bittner, V., Braun, L. T., Goff, D. C. Jr, Havas, S., Labarthe, D. R., Limacher, M. C., Lloyd-Jones, D. M., Mora, S., Pearson, T. A., Radford, M. J., Smetana, G. W., Spertus, J. A., Swegler, E. W. (2009). ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Circulation 120: 1296-1336 [Full text]  
• Scott, I. A (2009). Evaluating cardiovascular risk assessment for asymptomatic people. BMJ 338: a2844-a2844 [Full text]  
• Pfister, R., Hellmich, M., Austin, M. J., Heneghan, M. A., Zethelius, B., Venge, P., Arnlov, J. (2008). Multiple biomarkers and cardiovascular risk.. NEJM 359: 760-761 [Full text]  
• Pfister, R., Diedrichs, H., Schiedermair, A., Rosenkranz, S., Hellmich, M., Erdmann, E., Schneider, C. A. (2008). Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 10: 315-320 [Abstract] [Full text]  
• Brindle, P, Beswick, A, Fahey, T, Ebrahim, S (2006). Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92: 1752-1759 [Abstract] [Full text]  
• Rana, B S, Davies, J I, Band, M M, Pringle, S D, Morris, A, Struthers, A D (2006). B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 92: 916-920 [Abstract] [Full text]  
• Struthers, A.D., Davies, J. (2005). B-type natriuretic peptide: a simple new test to identify coronary artery disease?. QJM 98: 765-769 [Abstract] [Full text]  
• Masding, M., Gatling, W. (2004). Cardiovascular risk intervention in patients with type 2 diabetes. British Journal of Diabetes & Vascular Disease 4: 414-416 [Abstract]  
• Smith, J., Corrall, R., Leese, G. P, Hall, L., Jung, R. (2003). Cardiovascular risk scores and prescribing in diabetes. BMJ 326: 882-882 [Full text]  

Rapid Responses:

Read all Rapid Responses

STAY ALERT!!

ABDULLAH SHEHAB
bmj.com, 1 Feb 2003 [Full text]

Calculators exist

Trefor J Roscoe, et al.
bmj.com, 2 Feb 2003 [Full text]

Drawbacks of primary prevention risk tables to assess cardiovascular risk in type 2 diabetes

Jamie C Smith, et al.
bmj.com, 24 Feb 2003 [Full text]

Re: Drawbacks of primary prevention risk tables to assess cardiovascular risk in type 2 diabetes

Graham P Leese, et al.
bmj.com, 25 Feb 2003 [Full text]

Online poll

Find out more here>> and here>>